<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): September 24, 2008</B>

<P style="font-size: 24pt" align="center"><B>Osteotech, Inc.<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-19278</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>13-3357370</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>51 James Way, Eatontown, New
Jersey <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>07724</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(732) 542-2800</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>Not
Applicable<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;5.02 Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.</B>

<P style="font-size: 10pt" align="left">(d)&nbsp;&nbsp;On September&nbsp;24, 2008,
the Board of Directors (the &#8220;<I>Board</I>&#8221;) of Osteotech, Inc. (the
&#8220;<I>Company</I>&#8221;) elected Cato T. Laurencin, M.D., Ph.D., as an
independent director of the Board. The Company&#8217;s Board also named
Dr.&nbsp;Laurencin to serve on the Audit Committee and the Compensation
Committee of the Board.

<P style="font-size: 10pt; text-indent: 4%" align="left">Dr.&nbsp;Laurencin,
49, is currently the Vice President for Health Affairs at the University of
Connecticut Health Center and Dean of the University of Connecticut School of
Medicine. At the University of Connecticut, Dr.&nbsp;Laurencin also holds the
Albert and Wilda Van Dusen Endowed Chair in Academic Medicine and is a
Distinguished Professor of Orthopaedic Surgery. From February&nbsp;2003 until
August&nbsp;2008, Dr.&nbsp;Laurencin was the Lillian T. Pratt Distinguished
Professor and Chair of the Department of Orthopaedic Surgery at the University
of Virginia. Dr.&nbsp;Laurencin was also designated a University Professor by
the President of the University of Virginia. Prior to February&nbsp;2003, Dr.
Laurencin held various positions of increasing responsibility at Drexel
University, including the Helen I. Moorehead Distinguished Professor of
Chemical Engineering, Vice Chairman of the Department of Orthopaedic
Surgery and Director of Shoulder Surgery, and at MCP-Hahnemann School of Medicine, where he served as Clinical Professor of Orthopaedic Surgery and Research
Professor of Pharmacology and Physiology. Dr.&nbsp;Laurencin has a B.S.E.
degree in chemical engineering from Princeton University and earned his medical
degree from Harvard University Medical School. Dr. Laurencin also has a Ph.D.
in biochemical engineering/biotechnology from the Massachusetts Institute of
Technology.

<P style="font-size: 10pt; text-indent: 4%" align="left">There are no
arrangements or understandings between Dr.&nbsp;Laurencin and any other persons
pursuant to which Dr. Laurencin was selected as a director. Dr.&nbsp;Laurencin
does not have a direct or indirect material interest in any currently proposed
transaction to which the Company is to be party, nor has Dr.&nbsp;Laurencin had
a direct or indirect material interest in any such transaction since the
beginning of the Company&#8217;s last fiscal year. Dr.&nbsp;Laurencin has no
family relationships with any member of the Board or any other executive
officer of the Company.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;7.01 Regulation&nbsp;FD
Disclosure.</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">With the appointment
of Dr.&nbsp;Laurencin to serve on its Audit Committee, the Company
received notification from Nasdaq on September&nbsp;24, 2008, that it has regained
compliance with Nasdaq Marketplace Rule&nbsp;4350(d)(2), which requires that a
minimum of three members serve on the Company&#8217;s Audit Committee.
Osteotech previously reported that, due to the untimely passing of a member of
its Audit Committee, it had been notified by Nasdaq that it was not in
compliance with this Rule.

<P style="font-size: 10pt; text-indent: 4%" align="left">On September&nbsp;25,
2008, the Company issued a press release announcing the appointment of Cato T.
Laurencin, M.D., Ph.D. to serve as a member of its Board of Directors. A copy
of the press release is being furnished herewith as Exhibit&nbsp;99.1.

<P style="font-size: 10pt; text-indent: 4%" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01 Financial Statements
and Exhibits.</B>

<P style="font-size: 10pt" align="left">(d)&nbsp;Exhibit.

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">

 <TR
style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">99.1</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>Press release, dated September&nbsp;25, 2008, announcing the appointment
of Cato T. Laurencin, M.D., Ph.D. to the Board of Directors. This release is
being &#8220;furnished&#8221; and shall not be deemed &#8220;filed&#8221;
pursuant to Instruction B.2 of Form&nbsp;8-K</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">


<P style="font-size: 10pt" align="center"><B>SIGNATURE</B>

<P style="font-size: 10pt; text-indent: 2%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="45%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="50%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD valign="top" align="left" colspan="2">OSTEOTECH, INC.</TD>
 </TR>

<TR><TD>&nbsp;</TD></TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">By: </DIV></TD>
  <TD valign="top" align="left" style="border-bottom: #000000 1px solid">/s/ Mark H. Burroughs</TD>
 </TR>


 <TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Mark H. Burroughs<BR>
Executive Vice President</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="left">Date: September&nbsp;26, 2008

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>EXHIBIT INDEX</B>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>

 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>Exhibit<BR>Number</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Description</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release, dated September&nbsp;25, 2008,
announcing the appointment of Cato T. Laurencin, M.D., Ph.D. to the Board of
Directors. This release is being &#8220;furnished&#8221; and shall not be
deemed &#8220;filed&#8221; pursuant to Instruction B.2 of Form&nbsp;8-K</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">5
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c75521e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 12142}]
{"company-data": {"conformed-name": "OSTEOTECH INC", "cik": "0000874734", "assigned-sic": "3841", "irs-number": "133357370", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19278", "film-number": "081091331"}, "business-address": {"street1": "51 JAMES WAY", "city": "EATONTOWN", "state": "NJ", "zip": "07724", "phone": "7325422800"}, "mail-address": {"street1": "51 JAMES WAY", "city": "EATONTOWN", "state": "NJ", "zip": "07724"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): September 24, 2008
Osteotech, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-19278
13-3357370
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
51 James Way, Eatontown, New
Jersey
07724
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(732) 542-2800
Not
Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(d)  On September 24, 2008,
the Board of Directors (the "
Board
") of Osteotech, Inc. (the
"
Company
") elected Cato T. Laurencin, M.D., Ph.D., as an
independent director of the Board. The Company's Board also named
Dr. Laurencin to serve on the Audit Committee and the Compensation
Committee of the Board.
Dr. Laurencin,
49, is currently the Vice President for Health Affairs at the University of
Connecticut Health Center and Dean of the University of Connecticut School of
Medicine. At the University of Connecticut, Dr. Laurencin also holds the
Albert and Wilda Van Dusen Endowed Chair in Academic Medicine and is a
Distinguished Professor of Orthopaedic Surgery. From February 2003 until
August 2008, Dr. Laurencin was the Lillian T. Pratt Distinguished
Professor and Chair of the Department of Orthopaedic Surgery at the University
of Virginia. Dr. Laurencin was also designated a University Professor by
the President of the University of Virginia. Prior to February 2003, Dr.
Laurencin held various positions of increasing responsibility at Drexel
University, including the Helen I. Moorehead Distinguished Professor of
Chemical Engineering, Vice Chairman of the Department of Orthopaedic
Surgery and Director of Shoulder Surgery, and at MCP-Hahnemann School of Medicine, where he served as Clinical Professor of Orthopaedic Surgery and Research
Professor of Pharmacology and Physiology. Dr. Laurencin has a B.S.E.
degree in chemical engineering from Princeton University and earned his medical
degree from Harvard University Medical School. Dr. Laurencin also has a Ph.D.
in biochemical engineering/biotechnology from the Massachusetts Institute of
Technology.
There are no
arrangements or understandings between Dr. Laurencin and any other persons
pursuant to which Dr. Laurencin was selected as a director. Dr. Laurencin
does not have a direct or indirect material interest in any currently proposed
transaction to which the Company is to be party, nor has Dr. Laurencin had
a direct or indirect material interest in any such transaction since the
beginning of the Company's last fiscal year. Dr. Laurencin has no
family relationships with any member of the Board or any other executive
officer of the Company.
Item 7.01 Regulation FD
Disclosure.
With the appointment
of Dr. Laurencin to serve on its Audit Committee, the Company
received notification from Nasdaq on September 24, 2008, that it has regained
compliance with Nasdaq Marketplace Rule 4350(d)(2), which requires that a
minimum of three members serve on the Company's Audit Committee.
Osteotech previously reported that, due to the untimely passing of a member of
its Audit Committee, it had been notified by Nasdaq that it was not in
compliance with this Rule.
On September 25,
2008, the Company issued a press release announcing the appointment of Cato T.
Laurencin, M.D., Ph.D. to serve as a member of its Board of Directors. A copy
of the press release is being furnished herewith as Exhibit 99.1.
Item 9.01 Financial Statements
and Exhibits.
(d) Exhibit.
99.1
Press release, dated September 25, 2008, announcing the appointment
of Cato T. Laurencin, M.D., Ph.D. to the Board of Directors. This release is
being "furnished" and shall not be deemed "filed"
pursuant to Instruction B.2 of Form 8-K
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
OSTEOTECH, INC.
By:
/s/ Mark H. Burroughs
Mark H. Burroughs
Executive Vice President
Date: September 26, 2008
EXHIBIT INDEX
Exhibit
Number
Description
99.1
Press release, dated September 25, 2008,
announcing the appointment of Cato T. Laurencin, M.D., Ph.D. to the Board of
Directors. This release is being "furnished" and shall not be
deemed "filed" pursuant to Instruction B.2 of Form 8-K